In This Article:
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after market hours. Here’s what to look for.
Sarepta Therapeutics beat analysts’ revenue expectations by 4.3% last quarter, reporting revenues of $658.4 million, up 65.9% year on year. It was a mixed quarter for the company, with a significant miss of analysts’ EPS estimates.
Is Sarepta Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Sarepta Therapeutics’s revenue to grow 67.7% year on year to $693.5 million, improving from the 63.1% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.65 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Sarepta Therapeutics has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Sarepta Therapeutics’s peers in the therapeutics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. BioMarin Pharmaceutical delivered year-on-year revenue growth of 14.8%, beating analysts’ expectations by 1%, and United Therapeutics reported revenues up 17.2%, topping estimates by 5.6%. BioMarin Pharmaceutical traded down 1.3% following the results while United Therapeutics was also down 2.1%.
Read our full analysis of BioMarin Pharmaceutical’s results here and United Therapeutics’s results here.
There has been positive sentiment among investors in the therapeutics segment, with share prices up 4.9% on average over the last month. Sarepta Therapeutics is up 22.3% during the same time and is heading into earnings with an average analyst price target of $147.33 (compared to the current share price of $64.07).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.